Rocket Pharmaceuticals Inc (NASDAQ:RCKT) has received a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.50.
RCKT has been the subject of several recent analyst reports. ValuEngine raised Rocket Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. Evercore ISI began coverage on Rocket Pharmaceuticals in a research note on Tuesday, January 30th. They issued an “outperform” rating and a $27.00 target price for the company. Cowen began coverage on Rocket Pharmaceuticals in a research note on Friday, March 9th. They issued an “outperform” rating for the company. Finally, BidaskClub raised Rocket Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 5th.
Shares of RCKT stock traded up $0.55 during midday trading on Wednesday, hitting $17.60. The stock had a trading volume of 105,529 shares, compared to its average volume of 369,058. Rocket Pharmaceuticals has a 52 week low of $3.40 and a 52 week high of $19.97. The company has a quick ratio of 24.83, a current ratio of 24.83 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $671.80, a price-to-earnings ratio of -2.88 and a beta of 4.17.
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.